Page 14 - பீட்டர் மக்காலம் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Approval is based on CROWN trial, which showed a 72% reduction in risk of progression or death for treatment with LORBRENA vs. XALKORI ® The U.S. Food and Drug Administration approved Pfizer Inc.’s supplemental New Drug Application for LORBRENA ® expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase -positive non-small cell lung cancer . LORBRENA is now indicated for … Approval is based on CROWN trial, which showed a 72% reduction in risk of progression or death for treatment with LORBRENA vs. XALKORI ® The U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s (NYSE: PFE) supplemental New Drug Application (sNDA) for LORBRENA

United statesUnited kingdomAndy schmeltzBryan dunnEamonn nolanPeterss alectinibNational cancer institutePeter maccallum cancer centreWorld health organizationDrug administrationExchange commissionDepartment of medical oncologyPfizer incInternational agency for research on cancerEuropean unionEuropean medicines agency